108 results about "Intestinal injury" patented technology

The present invention relates to a glucagon-like peptide-2 (GLP-2) conjugate comprising native GLP-2 or its derivative and an immunoglobulin Fc fragment being covalently linked via a non-peptidyl polymer, wherein the native GLP-2 or its derivative has a thiol group introduced at its C-terminal end, and one end of the non-peptidyl polymer is linked to an amino acid residue of the GLP-2 other than the N-terminal amino group thereof; a method for preparing the GLP-2 conjugate; a pharmaceutical composition comprising the same; and a method for treating or preventing intestinal disease, intestinal injury, or gastrosia by using the same. Since the GLP-2 conjugate of the present invention has a remarkably increased binding affinity to a GLP-2 receptor, it shows a prolonged in vivo half-life and an improved in vivo durability and stability.

The invention discloses an application of an SIRT1 inhibitor in the prevention and treatment of radiation-induced enteric diseases, and concretely discloses a use of the SIRT1 inhibitor in the preparation of medicines, a medicinal composition for preventing or treating radiation-induced intestinal injury, and a method for treating or preventing the radiation-induced intestinal injury. Radiation-induced intestinal epithelial injury can effectively be prevented or treated, and the survival rate of animals is significantly improved, so the problem of lack of ideal therapeutic medicines and effective treatment methods for the radiation-induced intestinal injury is effectively solved.

The invention discloses a piglet compound feed and a preparation method thereof. The piglet compound feed comprises the following components in parts by weight: 20-50 parts of corn flour, 16-40 parts of extruded corn, 10-30 parts of fermented soybean meal, 11-25 parts of extruded soybean, 5-10 parts of wheat barn, 1-3 parts of bone meal, 4-6 parts of whey mist, 10-15 parts of milk powder, 1-5 parts of glucose, 0.02-0.04 part of compound vitamin, 0.1-0.3 part of compound mineral substance, 3-5 pars of balanced grease powder, 0.6-0.9 part of lysine, 0.6-0.9 part of methionine, 0.5-1.5 parts of xylooligosaccharide, 0.05-0.25 part of mannan oligosaccharide, 0.2-0.5 part of antimicrobial peptides, 0.1-0.3 part of an acidifier, 0.5-2 parts of cedrela sinensis leaves, 0.5-4 parts of cordate houttuynia, 0.5-3 parts of Chinese Magnoliavine Fruit, 0.5-3 parts of astragalus membranaceus, 0.5-3 parts of white atractylodes rhizome, 1.5-3 parts of malt, 2-6 parts of wolfiporia extensa, 0.15-0.6 parts of curcumin and 0.1-0.3 part of selenium yeast. The piglet compound feed is good in palatability and comprehensive for nutrition; while the development of the intestinal function of a weaning piglet in early stage is promoted, the intestinal injury caused by weaning is avoided, the diseases of piglet diarrhea and the like can be obviously reduced, and the resistance to diseases and growth rate of the piglet are improved.

An organotypic culture comprises an artificial stroma overlayed with epithelial cells isolated from a human colon or intestine. The stroma comprises a mixture of collagen and human fibroblasts isolated from a human colon or intestine. The culture contains a factor that binds the IGF-1 receptor, a factor that binds the EGF receptor, and a factor that binds the LIF receptor. These factors may be added exogenously to the culture via medium or may be expressed by various recombinantly engineered cell types in the culture. The organotypic culture can result in growth that is in situ-like or emphasizes other physiological or morphological states, depending on the balance of factors in the growth media. The organotypic culture may be used in methods for screening of therapeutic, carcinogenic, or growth enhancement factors, or for treating intestinal injuries by applying to the site of an injury the intact culture or the components thereof.

The disclosure provides methods and compositions for the use of IL-22 for treating conditions of intestinal injury and inflammatory conditions such as graft vs. host disease. Specifically, IL-22 can be used to increase Intestinal Stern Cell (ISC) recovery and for enhancing immune reconstitution following allogeneic hematopoietic transplantation. More specifically, the disclosure provides methods of using therapeutic IL-22, including a dimeric form of IL-22, in therapeutic compositions for treating graft vs. host disease, including hepatic, thymic, gastrointestinal, or other graft vs. host disease in hematopoietic stem cell transplant patients and in patients with inflammatory intestinal conditions.

The invention discloses a fur-animal-use composite premix, and belongs to the field of feedstuffs. The premix provided by the invention is prepared from the components of: vitamin C phosphate, methionine calcium, composite B vitamins, probiotics, and zeolite powder. The premix provided by the invention assists in enhancing supplies of nutrients such as trace elements, vitamins, and amino acids. With the premix, body immunity and stress resistance can be greatly improved, intestinal injury can be repaired, digestive discomfort can be relieved, digestive system function can be bidirectionally regulated, diarrhea and constipation can be controlled, and feedstuff efficiency can be improved. With the premix, vitamin C insufficiency caused by low addition or damages due to various physical and chemical factors can be supplemented, mother animal and young animal vitamin C deficiency can be prevented, and young animal red claw disease can be prevented and treated.

The invention discloses a composition comprising at least one long chain polyunsaturated fatty acid, at least one probiotic and a mixture of oligosaccharides, said mixture containing at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and / or in the prevention and / or treatment of intestinal inflammation, such as necrotizing enterocolis, and / or in the recovery after intestinal injury and / or surgery. This composition is particularly adapted for use in infants, notably preterm infants.

The invention provides for methods of protecting neurons within the enteric nervous system (ENS) comprising administering an EGF receptor agonist, such as heparin-binding EGF (HB-EGF). These methods include reducing damage of ENS neurons in patient s suffering from an intestinal injury. In addition, the invention provides for increasing intestinal motility in a patient suffering from an intestinal injury comprising administering HB-EGF. The invention also provides for methods of inducing neurite growth within the ENS in a patient suffering from intestinal injury comprising administering HB-EGF.

The invention is related to methods of protecting, preventing and reducing intestinal injury in a human subject suffering from or at risk for shock, hemorrhagic shock or hemorrhagic shock and resuscitation (HS / R) comprising administering heparin binding epidermal growth factor (HB-EGF). The invention is also related to methods of inhibiting deterioration of intestinal blood flow and methods of preserving and increasing intestinal blood flow by administering HB-EGF to a human subject. In addition, the methods of the invention should improve the clinical outcome of human subject suffering from or at risk for shock, hemorrhagic shock or hemorrhagic shock and resuscitation.

The invention belongs to the technical field of medicine, and relates to application of indolepopionic acid to preparation of drugs for preventing and / or treating tumor radiotherapy side effect. Through research, the fact that indolepopionic acid can obviously improve intestinal injury of mice, caused by gama ray irradiation, is found, the improvement shows that the survival rate of laboratory mice is obviously improved, the weight is risen again, the intestinal inflammation level is obviously reduced, and paradoxical reaction of the laboratory mice does not occur, the fact that indolepopionicacid can be effectively applied to the prevention and / or treatment of tumor radiotherapy side effect is shown, and the indolepopionic acid is low in toxic and side effect, and effective before and after being taken, and has a wide application potential.

The invention relates to a composite premixed feed for piglets and a preparation method and a feeding method thereof. The raw materials for preparing the finished product comprise, in percentage by weight, 0.8-2.5% of compound vitamins, 0.6-1.5% of compound amino acids, 15-35% of compound additives and the balance of montmorillonite. The preparation method is as follows: weighing the raw materialsaccording to the weight ratio, adding the raw materials into a mixer, and performing mixing for 40 minutes to ensure that the coefficient of uniformity variation of the raw materials is lower than 5%so as to obtain a finished product. Aiming at the physiological characteristics of easy diarrhea of weaned piglets, the scientific proportioning is carried out according to nutritional requirements.Therefore, the feed is reasonable in formula design and balanced and comprehensive in nutrients and suitable for piglet breeding, and can meet the special nutritional requirements for the growth and development and intestinal physiology of piglets, repair intestinal injury, achieve the effect of resisting diarrhea, enhance the digestion function of piglets, enhance the immunity and the disease resistance of the piglets, improve the feed intake of the piglets and the feed conversion rate, reduce the feed conversion ratio, improve the survival rate and the production performance, and obviously improve the growth speed of the piglets.

To promote the digestion of an animal to thereby elevate the feed efficiency or prevent or ameliorate intestinal infections such as inflammatory intestinal injury of the animal, a combination of at least one fungus selected from Aspergillus sojae, Aspergillus tamarii, Aspergillus foetidus, Aspergillus niger, and Aspergillus oryzae with an acidic enzyme produced by the fungus is administered to the animal.

The invention discloses lactobacillus paracasei capable of relieving alcoholic intestinal injury and an application of the lactobacillus paracasei capable of relieving alcoholic intestinal injury, andbelongs to the technical field of microorganisms and medicines, The invention provides a medicine capable of preventing and / or treating alcoholic intestinal injury or alcoholic liver injury. Effective components of the medicine are lactobacillus paracasei CCFM1120, and the lactobacillus paracasei CCFM1120 can effectively relieve the alcoholic intestinal injury and the alcoholic liver injury. Thelactobacillus paracasei has the specific effects that the mRNA expression level of intestine tight junction proteins of alcohol modeled mice can be notably increased, the content of endotoxin in serumof the alcohol modeled mice can be notably reduced, the activity of alanine aminotransferase and aspartate aminotransferase in the serum of the alcohol modeled mice can be notably reduced, the oxidation stress level of the liver of the alcohol modeled mice can be notably reduced, and the pathology damage of liver tissue of the alcohol modeled mice can be notably improved.

The invention discloses application of a miR-665-3p inhibitor to preparation of a medicine for preventing and treating ischemia-reperfusion injuries. The application proves that the miR-665-3p inhibitor can be used for remarkably improving the tolerance of intestinal cells on the ischemia-reperfusion injuries and alleviating the severity degree of the intestinal ischemia-reperfusion injuries; the miR-665-3p inhibitor is used for effectively alleviating phenomena of scaling and lodging of intestinal villi of mice, expansion and exposure of blood capillaries and the like; the miR-665-3p inhibitor can be used for remarkably inhibiting excessive releasing of intestinal injury marker intestinal fatty acid binding protein (I-FABP) and inflammatory cell factors including TNF-alpha and IL-6; and meanwhile, when the miR-665-3p inhibitor is used, the survival rate of mice subjected to mouse II / R injuries for 24h is remarkably higher than that of a control group.

The invention discloses novel application of a psyllium husk dietary fiber in intestinal injury. The taking dosage of the psyllium husk dietary fiber is 100mg / kg, and oral administration is adopted. The psyllium husk dietary fiber provided by the invention has the advantages that the pharmacological action is remarkable, the psyllium husk dietary fiber has the integrity of improving the intestinal injury, the translocation of intestinal floras is reduced, the expression of inflammatory factors in an intestinal tract is reduced, intestinal cell apoptosis is effectively reduced, and the toxic and side effects are small, so that, the psyllium husk dietary fiber can be used for preparing a drug or functional food for preventing the intestinal injury.

The invention discloses a composite additive for preventing prawn intestinal injury under the condition of low-fish-meal and high-soybean-meal feed and a preparation method of the composite additive and belongs to the technical field of aquatic feed additives. The composite additive comprises components in parts by mass as follows: 25-30 parts of fructooligosaccharide, 5-10 parts of tributyrin, 15-25 parts of glutamine dipeptide, 10-20 parts of white carbon black and 15-45 parts of defatted rice bran. The invention further discloses the preparation method of the composite additive for preventing the prawn intestinal injury under the condition of the low-fish-meal and high-soybean-meal feed. The composite additive can control breeding of pathogenic bacteria of prawn intestinal tracts under the condition of the low-fish-meal and high-soybean-meal feed, adjusts balance of intestinal flora, repair intestinal mucosa and maintain health of the intestinal mucosa. Besides, the activity of digestive enzyme of the intestinal tracts can be improved, the immune function is activated, and the prawn growth performance and the feed utilization efficiency are improved.

The invention discloses a composition comprising at least one long chain polyunsaturated fatty acid, at least one probiotic and a mixture of oligosaccharides, said mixture containing at least one N-acetylated oligosaccharide, at least one sialylated oligosaccharide and at least one neutral oligosaccharide, for use in the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and / or in the prevention and / or treatment of intestinal inflammation, such as necrotizing enterocolis, and / or in the recovery after intestinal injury and / or surgery. This composition is particularly adapted for use in infants, notably preterm infants.

The invention discloses a laying fowl feed additive and an application thereof. The laying fowl feed additive comprises the following raw materials in parts by weight: 20-50 parts of component A, 1-20 parts of B-group vitamin, 1-20 parts of component B, and 1-60 parts of medium-chain fatty acid, wherein the component A is coating short-chain fatty acid or coating short-chain fatty acid salt; the component B is at least one of beta-carotene, vitamin A, vitamin C and vitamin E; and the component B accounts for not larger than 1% of mass of the laying fowl feed additive. The component A, the B-group vitamin, the component B and the medium-chain fatty acid are adopted as main components, not only can the intestinal injury of laying fowl be restored, and can the physical quality of the laying fowl be enhanced, but also the development of fallopian tube of the laying fowl can be effectively promoted, and the inflammation of fallopian tube and ovary of the laying fowl can be diminished.

The invention discloses a composition for preventing and treating radioactive intestinal injuries. The composition comprises ferulic acid converted according to dosage 10-9mg / kg of an experiment mouse. The composition can be prepared into a clinically acceptable dosage form. The composition has an effect of preventing and treating the radioactive intestinal injuries, and the prevention and treatment of the radioactive intestinal injuries refer to improvement of capillary vessel injuries in intestinal villi, promotion of intestinal crypt stem cell proliferation and differentiation, promotion ofmucous epithelial cell regeneration, improvement of a cell state and a function of a hemopoietic system of the irradiated mouse by influencing a Thbd-aPC signal pathway and adjustment of an inflammatory factor HMGB1 (high mobility group box 1).

The invention provides application of syringaldehyde to preparation of medicine for preventing intestinal injuries caused by ionizing radiation, a pharmaceutical form and an administration mode.The medicine for preventing intestinal injuries caused by ionizing radiation with syringaldehyde as the active component has the advantages of being small in toxic and side effect, remarkable in treatment effect, convenient and safe to use and the like, is suitable for different people such as acute radiation syndrome patients, nuclear personnel, soldiers and officials, astronauts and radiotherapy patients, and can be used before treatment or task execution and during work.Syringaldehyde shows unique performance in prevention of intestinal injuries caused by ionizing radiation, and has wide application prospects in the medical field of China.

The invention provides application of cistanche total glycosides and echinacoside in preparation of medicines for preventing and treating alcoholic liver injury with intestinal injury and regulating intestinal flora. Pharmacological experiment results show that in an alcoholic liver injury mouse model, the cistanche total glycosides and echinacoside can relieve mouse liver tissue morphological injury, reduce mouse liver lipid deposition, reduce the content of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in mouse liver, relieve oxidative injury of mouse liver, and reduce damage of harmful substances such as endotoxin and the like to liver; and meanwhile, the mouse small intestine tissue form damage can be relieved, the intestinal wall villus integrity is improved, and the intestinal flora disorder is regulated. Therefore, the invention has the prospect of being developed into a medicine capable of simultaneously protecting the alcoholic liver injury and the alcoholic intestinal injury, and has important clinical significance and commercial value.

The invention discloses lactobacillus rhamnosus FLRH93. The lactobacillus rhamnosus FLRH93 is preserved in the Guangdong Microbial Culture Collection Center, and has a preservation number of GDMCC No:60956. Animal damage intervention experiment results show that the lactobacillus rhamnosus FLRH93 can obviously improve the intestinal injury caused by drugs; tissue staining sections show that the strain maintains the integrity of a small intestine structure, reduces the loss of goblet cells after drug treatment, and can regulate and control the secretion of Bcl-2 and NLRP3, thereby reducing generation of inflammatory factors IL1-beta and TNF-alpha. The invention belongs to the technical field of microorganisms. The strain provided by the invention can improve the survival rate of mice withdrug injury and can also remarkably promote healing of wound skin.

The invention discloses a pig feed for promoting intestinal development of piglets and application of the pig feed. According to the pig feed, a reasonable and scientific formula is adopted, digestive physiological characteristics and nutritional requirement of intestinal development of the piglets are considered fully, ingredients of whey powder, cane sugar, glucose, soybean oil and the like are added, the relevant property and the digestibility are improved, sufficient energy substances are provided for intestinal growth, inadequate energy supply of intestine during stress is relieved, internal cause of intestinal injury is considered, promotion of advanced intestinal maturation is considered, functional amino acids are utilized to promote intestinal growth, and proline provides a precursor of polyamine synthesis in a piglet intestine and can promote intestinal maturation to advance weaning day-old of the piglets.

The invention discloses an establishment method of an apoptosis model for inducing pig small intestinal epithelial cells by hydrogen peroxide. The establishment method comprises the following steps: preparing a cell culture medium; inoculating the pig small intestinal epithelial cells into the cell culture medium for culturing, and carrying out trypsin digestion treatment to obtain to-be-induced cells; and adding the cell culture medium containing the hydrogen peroxide into the to-be-induced cells and carrying out hydrogen peroxide induction. In the technical scheme provided by the invention,a cell apoptosis model is established by taking a pig small intestinal epithelial cell as a model cell for the first time and the hydrogen peroxide is used as an inducer; the establishment method hasthe advantages of short induction time, simple operation, low cost and stable and reliable effects; and the establishment of the cell apoptosis model provides an important way to study a pig intestinal injury mechanism and regulation measures thereof.

The invention belongs to the field of animal immunization and discloses an anti-chicken-coccidia Chinese herbal medicine microecological preparation and application thereof. The preparation comprisesbacillus amyloliquefaciens, enterococcus faecium, radix dichroae and radix sophorae flavescentis. According to the preparation, Chinese herbal medicine is combined with probiotics for use, the effectsof mutual promotion and synergism are achieved, the medicine application amount is reduced, the content of IFN-gamma and IL-2 in chicken bodies can be obviously increased, the cellular immune response of the chicken bodies is improved, and accordingly the obvious anti-chicken-coccidia effect is achieved; meanwhile, the intestinal injury can be avoided, a certain repairing function on the intestinal injury is achieved, the weight of the chicken bodies is increased, and the preparation is suitable for large-scale application and popularization.

The invention belongs to the field of medicine technology, which relates to a medical animal model, in particular to an establishment method for a plateau intestinal barrier injury rat model. The method comprises the following steps of: firstly, feeding healthy rats for 5-7 days in a plain environment, then carrying out the animal treadmill adaptive training to obtain plain adaptive rats, and then carrying out plain intervention training for the plain adaptive rats by applying exercise load, so that the plain adaptive rats can reach to be in a fatigue stress state; continuously feeding the rats which reach to be in the fatigue stress state in a plateau hypobaric hypoxia simulation environment to obtain the experimental plateau intestinal barrier injury rat model. The method can establish the stable plateau intestinal barrier injury rat model, so that the experimental foundation for further research on the plateau intestinal injury mechanism is laid.

Provided are a glucagon-like peptide-2 (GLP-2) conjugate containing native GLP-2 or its derivative and an immunoglobulin Fc fragment being covalently linked via a non-peptidyl polymer, wherein the native GLP-2 or its derivative has a thiol group introduced at its C-terminal end, and one end of the non-peptidyl polymer is linked to an amino acid residue of the GLP-2 other than the N-terminal amino group thereof; a method for preparing the GLP-2 conjugate; a pharmaceutical composition comprising the same; and a method for treating or preventing intestinal disease, intestinal injury, or gastrosis by using the same. Since the GLP-2 conjugate of the present invention has a remarkably increased binding affinity to a GLP-2 receptor, it shows a prolonged in vivo half-life and an improved in vivo durability and stability.

The invention provides for methods of protecting neurons within the enteric nervous system (ENS) comprising administering an EGF receptor agonist, such as heparin-binding EGF (HB-EGF). These methods include reducing damage of ENS neurons in patient s suffering from an intestinal injury. In addition, the invention provides for increasing intestinal motility in a patient suffering from an intestinal injury comprising administering HB-EGF. The invention also provides for methods of inducing neurite growth within the ENS in a patient suffering from intestinal injury comprising administering HB-EGF.

The invention provides a rectum detection device. The rectum detection device comprises a core rod, a balloon, a balloon liquid filling device and a rectum liquid or gas injection device. The outer wall of the core rod is covered by the balloon, and the core rod has a light guide function or a self-illumination function. The rectum detection device has the advantages that iatrogenic intestinal injuries can be avoided, and rectum lesion positions, injury conditions and injury positions can be accurately judged by cooperation of a laparoscope light source.